Beschreibung

Semaglutide is a GLP-1 analogue that selectively binds to the GLP-1 receptor, thereby promoting the secretion of insulin from pancreatic beta cells in a glucose-dependent manner. At the same time, glucagon secretion from the alpha cells is inhibited and insulin sensitivity is increased. These effects are mediated by an increase in intracellular cAMP levels and a resulting activation of protein kinase A via a GS receptor.

There is also slowed gastric emptying and an increased feeling of satiety, which is probably mediated via peptidergic, proglucagon-expressing neurons in the nucleus tractus solitarii of the brainstem. These neurons transmit signals from the stretch receptors of the stomach wall by releasing glucagon-like peptide-1.[1] Due to this positive side effect, semaglutide contributes to weight loss in overweight diabetics.